A phase 3 pivotal study of PL9643, a melanocortin agonist under investigation as a treatment for dry eye disease, demonstrated positive interim results, according to a press release from Palatin Technologies.
The analysis included efficacy and safety data from 120 participants in the multicenter, randomized, double-masked, vehicle-controlled MELODY-1 clinical study. Based on a review of the data, an independent data monitoring committee recommended that the study continue with a sample size target of up to 350 participants.
“The emerging data, including the safety and ocular tolerability,